- Initial dose: 300 mg SC at weeks 0, 1, 2, 3, and 4
- Maintenance dose: 300 mg q4wks
- Each 300 mg dose is given as 2 SC INJ of 150 mg
- For some patients, a dose of 150 mg may be acceptable
- Initial dose: 300 mg SC at weeks 0, 1, 2, 3, and 4
- Maintenance dose: 300 mg q4wks
- Each 300 mg dose is given as 2 SC INJ of 150 mg
- For some patients, a dose of 150 mg may be acceptable
- Administer secukinumab with or without a loading dosage by SC injection
- Recommended dose:
- With a loading dosage: 150 mg at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter
- Without a loading dosage: 150 mg every 4 weeks
- If a patient continues to have active psoriatic arthritis, consider a dosage of 300 mg
- Secukinumab may be administered with or without methotrexate
- Administer secukinumab with or without a loading dosage by subcutaneous injection
- The recommended dosage:
- With a loading dosage: 150 mg at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter
- Without a loading dosage: 150 mg every 4 weeks
Note:
- Prior to initiating treatment evaluate the patients for tuberculosis (TB) infection
- Refer package insert for administration instructions, preparation for use of Sensoready pen and prefilled syringe, and reconstitution and preparation of lyophilized powder
- Safety and efficacy in pediatric patients have not been established
